Anakinra

Hospital Pharmacy

Volumn 37, Issue 6, 2002, Pages 619-626

  Cada, Dennis J ^a   Levien, Terri ^a   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOMODULATION; NAUSEA; REVIEW; RHEUMATOID ARTHRITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0036281497     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870203700609     Document Type: Review

References (36)

1. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist
2. Uncoupling of inflammatory and destructive mechanisms in arthritis
3. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis
4. Joint inflammation and cartilage destruction may occur uncoupled
5. Anti-cytokine therapy for rheumatoid arthritis
6. Kineret (anakinra) (recombinant methionyl human interleukin-1 receptor antagonist)
7. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
8. Selective inhibition of IL-1B induced proinflammatory gene expression by recombinant IL-1 receptor antagonist (IL-1RA; anakinra) in human whole blood cultures: Contrast to other anti-inflammatory agents
9. Efficacy of treatment with anakinra in combination with other therapeutics in rat models of arthritis
10. Synergistic effect of IL1RA and etanercept on inhibition of human chondrocytes responses to cytokines derived from anti-CE3/CD28 stimulated human PBMC
11. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1
12. Elevated levels of soluble interleukin-1 receptor type II and interluekin-1 receptor antagonist in patients with chronic arthritis: Correlations with markers of inflammation and joint destruction
13. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans
14. Population pharmacokinetics of recombinant interluekin-1 receptor antagonist (anakinra) in subjects with rheumatoid arthritis (RA)
15. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
16. Update in rheumatology
17. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
18. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis
19. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
20. Increases in productivity after six and twelve months of anakinra treatment in patients with rheumatoid arthritis
21. Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the second 6 months of treatment for patients with rheumatoid arthritis
22. Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis
23. Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: Radiologic assessment
24. Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: Radiologic progression and correlation of Genant/Sharp and Larsen scoring methods
25. The impact of anakinra therapy on patient-centered outcomes in rheumatoid arthritis
26. Treatment of interleukin1 receptor antagonist in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients
27. IL1-ra improves health-related quality of life as measured by the health assessment questionnaire
28. Characterizing the health-related quality of life effects of IL1-ra therapy as measured by the health assessment questionnaire
29. Anakinra (recombinant interleukin-1 receptor antagonist): A large, placebo-controlled efficacy trial of anakinra in patients with erosive rheumatoid arthritis disease
30. Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis
31. A safety trial of anakinra: Recombinant interleukin-1 receptor antagonist (IL-1RA), in a large, placebocontrolled heterogeneous population of patients with rheumatoid arthritis
32. Pharmacokinetics (PK) of neither anakinra (interleukin-1 receptor antagonist, IL-1ra) nor pegylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) were altered after combination treatment in subjects with rheumatoid arthritis (RA)